



DIVISION OF
CORPORATION FINANCE

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

April 16, 2024

Cris Calsada
Chief Financial Officer
Regulus Therapeutics Inc.
4224 Campus Point Court, Suite 210
San Diego, California 92121

Re: Regulus Therapeutics Inc.
Registration Statement on Form S-3
Filed April 9, 2024
File No. 333-278581

Dear Cris Calsada:

This is to advise you that we have not reviewed and will not review your registration statement.

Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.

Please contact Jimmy McNamara at 202-551-7349 with any questions.

Sincerely,

Division of Corporation Finance
Office of Life Sciences

cc: Asa Michael Henin